
## Bianca Rocca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1583152/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of	0.8	77
2	Association of Platelet Thromboxane Inhibition by Lowâ€Dose Aspirin With Platelet Count and Cyperia Cytoreductive Therapy in Essential Thrombocythemia. Clinical Pharmacology and Therapeutics, 2022, 111, 939-949.	2.3	6
3	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. HemaSphere, 2022, 6, e750.	1.2	29
4	Less Thromboxane, Longer Life. Journal of the American College of Cardiology, 2022, 80, 251-255.	1.2	4
5	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2022 Congress. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12747.	1.0	4
6	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 125-140.	1.4	31
7	The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovascular Research, 2021, 117, 2001-2015.	1.8	55
8	Antithrombotic therapy in diabetes: which, when, and for how long?. European Heart Journal, 2021, 42, 2235-2259.	1.0	29
9	Sirtuin 5, vascular endothelium and fibrinolysis: a deadly embrace?. Cardiovascular Research, 2021, 117, 2145-2147.	1.8	Ο
10	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal, 2021, 42, 2265-2269.	1.0	81
11	Platelets, coagulation, and the vascular wall: the quest to better understand and smarten up our therapeutic targeting of this triad in primary and secondary prevention of cardiovascular events. Cardiovascular Research, 2021, 117, 1998-2000.	1.8	1
12	How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. Journal of Cardiovascular Medicine, 2021, 22, 924-928.	0.6	4
13	Aspirin at 120: Retiring, recombining, or repurposing?. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12516.	1.0	6
14	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
15	In vivo thromboxaneâ€dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. Diabetes/Metabolism Research and Reviews, 2020, 36, e3232.	1.7	14
16	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. Diabetes Research and Clinical Practice, 2020, 160, 108008.	1.1	18
17	From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 2020, 34, 143-144.	1.3	1
18	Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European Heart Journal Supplements, 2020, 22, M26-M34.	0.0	5

#	Article	IF	CITATIONS
19	389 ASPIRIN REDUCES PGE2 BIOSYNTHESIS TO LEVELS ASSOCIATED WITH REDUCED RISK OF ADENOMA AND COLORECTAL CANCER: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL Gastroenterology, 2020, 158, S-70.	0.6	0
20	Effect of Low-dose and Standard-dose Aspirin on PGE2 Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial. Cancer Prevention Research, 2020, 13, 877-888.	0.7	23
21	The ESC Working Group on Thrombosis. European Heart Journal, 2020, 41, 3130-3131.	1.0	0
22	Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 413-421.	1.0	9
23	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood, 2020, 136, 171-182.	0.6	65
24	Pathophysiology of Thrombosis in Peripheral Artery Disease. Current Vascular Pharmacology, 2020, 18, 204-214.	0.8	17
25	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Econcermedicalscience, 2020, 14, 998. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial	0.6	4
26	fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care	0.7	209
27	(ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193. Measurement of Thromboxane Biosynthesis in Health and Disease. Frontiers in Pharmacology, 2019, 10, 1244.	1.6	55
28	Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. Journal of Cellular Physiology, 2019, 234, 15459-15471.	2.0	19
29	Obesity is associated with impaired responsiveness to onceâ€daily lowâ€dose aspirin and in vivo platelet activation. Journal of Thrombosis and Haemostasis, 2019, 17, 885-895.	1.9	37
30	Characterization of aspirin esterase activity in health and disease: In vitro and ex vivo studies. Biochemical Pharmacology, 2019, 163, 119-127.	2.0	5
31	Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 2019, 30, 148-157.	1.1	25
32	Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease. European Journal of Preventive Cardiology, 2019, 26, 92-105.	0.8	4
33	Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. , 2019, 234, 15459.		1
34	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 2018, 39, 1672-1686f.	1.0	106
35	More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions. Journal of the American Heart Association, 2018, 7, .	1.6	11
36	Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin. Ecancermedicalscience, 2018, 12, 813.	0.6	4

#	Article	IF	CITATIONS
37	Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction. Blood Advances, 2018, 2, 715-730.	2.5	38
38	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	1.0	1,396
39	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer Journal, 2018, 8, 49.	2.8	30
40	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2017, 38, ehw454.	1.0	86
41	Type 2 Diabetes, Obesity, and Aspirin Responsiveness. Journal of the American College of Cardiology, 2017, 69, 613-615.	1.2	28
42	Onâ€pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. Clinical Pharmacology and Therapeutics, 2017, 102, 849-858.	2.3	24
43	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus	1.2	140
44	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de	0.7	107
45	Summayið <sup>P</sup> a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association	1.8	41
46	and Sociedad Latinoamericana de Es. Thrombosis and Haemostasis, 2017, 117, 2215-2236. Steen Elkjær Husted MD FESC 1950–2016. European Heart Journal, 2017, 38, 472-472.	1.0	0
47	Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. Thrombosis and Haemostasis, 2016, 116, 891-896.	1.8	15
48	Aspirin, stroke and drug-drug interactions. Vascular Pharmacology, 2016, 87, 14-22.	1.0	23
49	Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes. Drugs and Aging, 2016, 33, 233-248.	1.3	6
50	In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. Diabetes, 2016, 65, 503-509.	0.3	43
51	Unmet Clinical Needs of Antithrombotic Treatment in BCR/ABL-Negative Myeloproliferative Neoplasms. , 2016, , 379-393.		0
52	Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. Journal of Thrombosis and Haemostasis, 2015, 13, 1226-1237.	1.9	48
53	Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice. Thrombosis and Haemostasis, 2015, 114, 1218-1229.	1.8	11
54	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2015, 36, ehv304.	1.0	175

#	Article	IF	CITATIONS
55	Platelet progenitors: the hidden drug target. European Heart Journal, 2015, 36, 3211-3213.	1.0	12
56	Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2015, 31, 402-410.	1.7	82
57	In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. Thrombosis and Haemostasis, 2014, 112, 118-127.	1.8	19
58	Stability of Urinary Thromboxane A2 Metabolites and Adaptation of the Extraction Method to Small Urine Volume. Clinical Laboratory, 2014, 60, 105-11.	0.2	9
59	Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood, 2013, 121, 1701-1711.	0.6	78
60	Identifying determinants of variability to tailor aspirin therapy. Expert Review of Cardiovascular Therapy, 2013, 11, 365-379.	0.6	23
61	Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood, 2012, 119, 3595-3603.	0.6	187
62	Aspirin and Other COX-1 Inhibitors. Handbook of Experimental Pharmacology, 2012, , 137-164.	0.9	24
63	Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. Thrombosis, 2012, 2012, 1-11.	1.4	48
64	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to lowâ€dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 2012, 10, 1220-1230.	1.9	211
65	Successful Pregnancy in a Living-Related Kidney Transplant Recipient Who Received Sirolimus Throughout the Whole Gestation. Transplantation, 2011, 91, e69-e71.	0.5	43
66	Prostaglandin E2Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 391-402.	1.3	45
67	Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge andin vivourinary thromboxane production in healthy male subjects. Stress, 2011, 14, 282-289.	0.8	20
68	The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood, 2010, 115, 1054-1061.	0.6	100
69	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radical Biology and Medicine, 2010, 48, 446-456.	1.3	56
70	Clinical and laboratory phenotype associated with the aspirinâ€like defect. British Journal of Haematology, 2010, 148, 661-663.	1.2	3
71	Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB Journal, 2010, 24, 3970-3980.	0.2	75
72	The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine, 2010, 61, 49-61.	5.0	24

#	Article	IF	CITATIONS
73	Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: Effects on platelet function in the systemic circulation and across the filter. Thrombosis Research, 2010, 126, 24-31.	0.8	16
74	Personalized Medicine, Pharmacogenetics, and Clopidogrel: Unraveling Variability of Response. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2010, 10, 12-19.	3.4	7
75	Breast Cancer in Pregnancy: Report of 12 cases. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 146, 111-112.	0.5	1
76	Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thrombosis Research, 2009, 124, 96-100.	0.8	36
77	Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Journal of the American College of Cardiology, 2009, 53, 667-677.	1.2	234
78	Nonsteroidal antiinflammatory drugs: Past, present and futureâ~†. Pharmacological Research, 2009, 59, 285-289.	3.1	70
79	Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica, 2009, 94, 1368-1374.	1.7	53
80	Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Human Mutation, 2008, 29, 409-417.	1.1	172
81	ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN POLYCYTHEMIA VERA. European Journal of Internal Medicine, 2008, 19, S16.	1.0	0
82	Aspirin: Promise and Resistance in the New Millennium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, s25-32.	1.1	91
83	Fibrinogen-elongated Î <sup>3</sup> Chain Inhibits Thrombin-induced Platelet Response, Hindering the Interaction with Different Receptors. Journal of Biological Chemistry, 2008, 283, 30193-30204.	1.6	34
84	Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood, 2008, 112, 1085-1090.	0.6	29
85	Letters. Spine, 2008, 33, 827.	1.0	1
86	Drug Insight: aspirin resistance—fact or fashion?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 42-50.	3.3	111
87	Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs?. Nature Clinical Practice Rheumatology, 2007, 3, 316-317.	3.2	3
88	Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents. Journal of Applied Physiology, 2007, 103, 1412-1418.	1.2	36
89	Authors' response to "Drug Insight: aspirin resistance—fact or fashion?― Nature Clinical Practice Cardiovascular Medicine, 2007, 4, E2-E2.	3.3	0
90	Pregnancy after liver transplantation: Report of 8 new cases and review of the literature. Transplant Immunology, 2006, 15, 297-302.	0.6	61

#	Article	IF	CITATIONS
91	Targeting PGE2 Receptor Subtypes Rather Than Cyclooxygenases: A Bridge Over Troubled Water?. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 68-73.	3.4	8
92	Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery. Neuromuscular Disorders, 2005, 15, 532-540.	0.3	40
93	Prostanoid Generation in Platelet Function. , 2005, , 267-281.		0
94	Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 246-255.	1.1	135
95	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. Experimental Hematology, 2004, 32, 925-934.	0.2	13
96	Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2. Science, 2002, 296, 539-541.	6.0	775
97	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7634-7639.	3.3	295
98	Cyclooxygenases and prostaglandins: shaping up the immune response. International Immunopharmacology, 2002, 2, 603-630.	1.7	200
99	Distinct expression of cyclooxygenase-1 and -2 in the human thymus. European Journal of Immunology, 2002, 32, 1482.	1.6	14
100	TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage. Journal of Leukocyte Biology, 2002, 72, 986-94.	1.5	14
101	Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nature Medicine, 2000, 6, 219-221.	15.2	54
102	Cardiovascular Responses to the Isoprostanes iPF <sub>2α</sub> -III and iPE <sub>2</sub> -III Are Mediated via the Thromboxane A <sub>2</sub> Receptor In Vivo. Circulation, 2000, 101, 2833-2840.	1.6	194
103	Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. Journal of Clinical Investigation, 1999, 103, 1469-1477.	3.9	120
104	Simply Read: Erythrocytes Modulate Platelet Function. Circulation, 1997, 95, 11-13.	1.6	20
105	Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Critical Reviews in Oncology/Hematology, 1995, 20, 203-222.	2.0	74
106	Increased Thromboxane Biosynthesis in Essential Thrombocythemia. Thrombosis and Haemostasis, 1995, 74, 1225-1230.	1.8	88
107	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecancermedicalscience, 0, 14, .	0.6	0